Revised physician labelling for neuroleptic drugs: Food and Drug Administration. Notice.
This notice requires that a precaution statement be included in physician labeling of neuroleptic drugs (except rauwolfia alkaloids) stating that these drugs elevate serum prolactin levels and may pose a potential risk to patients.
D014150:Antipsychotic Agents / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000209:etiology; D004348:Drug Labeling / Q000592:standards*; D005260:Female; D006801:Humans; D012306:Risk; D014481:United States; D014486:United States Food and Drug Administration